Cargando…

Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach

PURPOSE: Changes in drug absorption and first-pass metabolism have been reported throughout the pediatric age range. Our aim is to characterize both intestinal and hepatic CYP3A-mediated metabolism of midazolam in children in order to predict first-pass and systemic metabolism of CYP3A substrates. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Brussee, Janneke M., Yu, Huixin, Krekels, Elke H. J., Palić, Semra, Brill, Margreke J. E., Barrett, Jeffrey S., Rostami-Hodjegan, Amin, de Wildt, Saskia N., Knibbe, Catherijne A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096899/
https://www.ncbi.nlm.nih.gov/pubmed/30062590
http://dx.doi.org/10.1007/s11095-018-2458-6
_version_ 1783348191777783808
author Brussee, Janneke M.
Yu, Huixin
Krekels, Elke H. J.
Palić, Semra
Brill, Margreke J. E.
Barrett, Jeffrey S.
Rostami-Hodjegan, Amin
de Wildt, Saskia N.
Knibbe, Catherijne A. J.
author_facet Brussee, Janneke M.
Yu, Huixin
Krekels, Elke H. J.
Palić, Semra
Brill, Margreke J. E.
Barrett, Jeffrey S.
Rostami-Hodjegan, Amin
de Wildt, Saskia N.
Knibbe, Catherijne A. J.
author_sort Brussee, Janneke M.
collection PubMed
description PURPOSE: Changes in drug absorption and first-pass metabolism have been reported throughout the pediatric age range. Our aim is to characterize both intestinal and hepatic CYP3A-mediated metabolism of midazolam in children in order to predict first-pass and systemic metabolism of CYP3A substrates. METHODS: Pharmacokinetic (PK) data of midazolam and 1-OH-midazolam from 264 post-operative children 1–18 years of age after oral administration were analyzed using a physiological population PK modelling approach. In the model, consisting of physiological compartments representing the gastro-intestinal tract and liver,intrinsic intestinal and hepatic clearances were estimated to derive values for bioavailability and plasma clearance. RESULTS: The whole-organ intrinsic clearance in the gut wall and liver were found to increase with body weight, with a 105 (95% confidence interval (CI): 5–405) times lower intrinsic gut wall clearance than the intrinsic hepatic clearance (i.e. 5.08 L/h (relative standard error (RSE) 10%) versus 527 L/h (RSE 7%) for a 16 kg individual, respectively). When expressed per gram of organ, intrinsic clearance increases with increasing body weight in the gut wall, but decreases in the liver, indicating that CYP3A-mediated intrinsic clearance and local bioavailability in the gut wall and liver do not change with age in parallel. The resulting total bioavailability was found to be age-independent with a median of 20.8% in children (95%CI: 3.8–50.0%). CONCLUSION: In conclusion, the intrinsic CYP3A-mediated gut wall clearance is substantially lower than the intrinsic hepatic CYP3A-mediated clearance in children from 1 to 18 years of age, and contributes less to the overall first-pass metabolism compared to adults. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11095-018-2458-6) contains, which is available to authorized users.
format Online
Article
Text
id pubmed-6096899
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-60968992018-08-24 Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach Brussee, Janneke M. Yu, Huixin Krekels, Elke H. J. Palić, Semra Brill, Margreke J. E. Barrett, Jeffrey S. Rostami-Hodjegan, Amin de Wildt, Saskia N. Knibbe, Catherijne A. J. Pharm Res Research Paper PURPOSE: Changes in drug absorption and first-pass metabolism have been reported throughout the pediatric age range. Our aim is to characterize both intestinal and hepatic CYP3A-mediated metabolism of midazolam in children in order to predict first-pass and systemic metabolism of CYP3A substrates. METHODS: Pharmacokinetic (PK) data of midazolam and 1-OH-midazolam from 264 post-operative children 1–18 years of age after oral administration were analyzed using a physiological population PK modelling approach. In the model, consisting of physiological compartments representing the gastro-intestinal tract and liver,intrinsic intestinal and hepatic clearances were estimated to derive values for bioavailability and plasma clearance. RESULTS: The whole-organ intrinsic clearance in the gut wall and liver were found to increase with body weight, with a 105 (95% confidence interval (CI): 5–405) times lower intrinsic gut wall clearance than the intrinsic hepatic clearance (i.e. 5.08 L/h (relative standard error (RSE) 10%) versus 527 L/h (RSE 7%) for a 16 kg individual, respectively). When expressed per gram of organ, intrinsic clearance increases with increasing body weight in the gut wall, but decreases in the liver, indicating that CYP3A-mediated intrinsic clearance and local bioavailability in the gut wall and liver do not change with age in parallel. The resulting total bioavailability was found to be age-independent with a median of 20.8% in children (95%CI: 3.8–50.0%). CONCLUSION: In conclusion, the intrinsic CYP3A-mediated gut wall clearance is substantially lower than the intrinsic hepatic CYP3A-mediated clearance in children from 1 to 18 years of age, and contributes less to the overall first-pass metabolism compared to adults. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11095-018-2458-6) contains, which is available to authorized users. Springer US 2018-07-30 2018 /pmc/articles/PMC6096899/ /pubmed/30062590 http://dx.doi.org/10.1007/s11095-018-2458-6 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Paper
Brussee, Janneke M.
Yu, Huixin
Krekels, Elke H. J.
Palić, Semra
Brill, Margreke J. E.
Barrett, Jeffrey S.
Rostami-Hodjegan, Amin
de Wildt, Saskia N.
Knibbe, Catherijne A. J.
Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
title Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
title_full Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
title_fullStr Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
title_full_unstemmed Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
title_short Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach
title_sort characterization of intestinal and hepatic cyp3a-mediated metabolism of midazolam in children using a physiological population pharmacokinetic modelling approach
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096899/
https://www.ncbi.nlm.nih.gov/pubmed/30062590
http://dx.doi.org/10.1007/s11095-018-2458-6
work_keys_str_mv AT brusseejannekem characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach
AT yuhuixin characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach
AT krekelselkehj characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach
AT palicsemra characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach
AT brillmargrekeje characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach
AT barrettjeffreys characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach
AT rostamihodjeganamin characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach
AT dewildtsaskian characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach
AT knibbecatherijneaj characterizationofintestinalandhepaticcyp3amediatedmetabolismofmidazolaminchildrenusingaphysiologicalpopulationpharmacokineticmodellingapproach